Look back at pharma news in the week to June 21

23 June 2019

By Barbara Obstoj-Cardwell. Editor

On the dealing-making front, there was double-edged news for Sino-American drug developer BeiGene last Monday, as Celgene returned rights to cancer candidate tislelizumab. Also, Sanofi and its Genzyme unit took another step into withdrawing from its deal with Voyager Therapeutics on gene therapies. M&A news featured an $11.4 billion bid by Pfizer for Array BioPharma, while regulatory news included Melinta Therapeutics getting a boost from the news that the Food and Drug Administration had accepted for priority review its New Drug Application for Baxdela as a treatment for community-acquired bacterial pneumonia.

Celgene returns global tislelizumab rights ahead of acquisition as anticipated

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK